Purple Biotech (PPBT) reported final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

However, there were some signals that could keep the anti-inflammatory agent in the game. An exploratory composite outcome of ...

The ENDEAVOR trial showed that in patients with HFpEF or HFmrEF, the myeloperoxidase inhibitor mitiperstat did not improve symptoms or 6-minute walk distance. Patients with symptomatic HFpEF or HFmrEF ...